Tag: Sanofi

FDA Approved Expanded Indication for Sanofi’s Toujeo

Sanofi
The U.S. Food and Drug Administration (FDA) approved an expanded indication for Sanofi’s Toujeo (insulin glargine injection) for blood sugar control in adult and pediatric patients who are ages six ye...

Sanofi Launched Dupixent® in Russia

sanofi
Sanofi announced the launch of the Dupixent® on the Russian market for the treatment of patients with moderate to severe atopic dermatitis aged 18 years and older and as an additional supportive thera...

Sanofi and Nanolek Begin Localisation of Menactra Vaccine

nanolek
Sanofi and Nanolek announced a new stage in the development of a long-term partnership - the beginning of a project to localize the production of Menactra® vaccine. The partnership will help expand th...

FDA Approved Fluzone® High-Dose Quadrivalent for Adults 65 years of Age and Older

The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and olde...

Sanofi Announced Agreement to Settle Contingent Value Rights Litigation

Sanofi
Sanofi announced that it has entered into an agreement to settle (the “Settlement Agreement”) the previously disclosed action UMB Bank, N.A., as Trustee v. Sanofi (No. 15 Civ. 8725 (GBD) (the “Action”...

European Commission Approved New Indication for Dupixent®

The European Commission (EC) approved a new indication for Dupixent® (dupilumab) in chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add-on therapy with intranasal c...

Sanofi Announced Voluntary Recall of Zantac in the U.S. and Canada

Sanofi announced that it is carrying out a voluntary recall of over-the-counter (OTC) Zantac (ranitidine) in the US and Canada as a precautionary measure due to possible contamination with N-nitrosodi...

Sanofi Opened New Digital Manufacturing Facility in Framingham

Sanofi celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world’s first digital facilities using intensified, continuous biologics p...

Sanofi to Launch Its Type II Diabetes Treatment in UK

sanofi
Sanofi has launched Suliqua (insulin glargine/lixisenatide), its type II diabetes treatment, in the UK. The approval of the once-daily injection is based on two phase III studies, LixiLan-O and Lix...

Regeneron and Sanofi Announced Positive Results from Two Phase 3 Trials Evaluating Dupixent®

regeneron
Regeneron Pharmaceuticals, Inc. and Sanofi announced that The Lancet has published detailed positive results from two Phase 3 trials evaluating the safety and efficacy of Dupixent® (dupilumab) in adul...

Sanofi & Abbott Agreed to Integrate Glucose Sensing and Insulin Delivery Technologies

insulin syringe
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies w...

BI, Eli Lilly, Sanofi, Servier Develop Drug-Drug Interaction Risk Calculator

Elsevier, an information analytics business, is working together with a set of evaluation partners including Boehringer Ingelheim, Eli Lilly, Pierre Fabre, Sanofi, Servier, and others to develop a new...

Sanofi Will Pay to Lexicon for Partnership Termination

Lexicon Pharmaceuticals Inc said on Tuesday that France’s Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista. Shares of Lexico...

Zentiva Group to Acquire Sanofi’s Production Facilities in India

zentiva
Zentiva Group announced a transfer agreement with Sanofi to acquire production facilities in Ankleshwar, India. With this acquisition, Zentiva is expanding its operations and capabilities of its manuf...

U.S. District Court Rules in Favor of Sanofi and Regeneron in Praluent® Patent Litigation

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for...

Regeneron and Sanofi Announced Positive Pivotal Phase 3 Trial of Dupixent®

clinical-trial
Regeneron Pharmaceuticals, Inc. and Sanofi announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and ...